#ECTRIMS2022 ā ATA188 Could Be ‘Game Changing’ for Progressive MS
In an early clinical trial, Atara Biotherapeuticsā investigational treatment ATA188 stabilized or eased disability in most people with nonactive, progressive forms of multiple sclerosis (MS) ā with those benefits now having been sustained for up to four years. For MS patients, in whom disability progressively accumulates over time,…